Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 4Ovarian Neoplasms 2Neoplasms 2Uterine Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 13pembrolizumab 8Carboplatin 7Surveys and Questionnaires 6Cisplatin 6Brachytherapy 5Doxorubicin 4Docetaxel 4Pemetrexed 3Hyperthermic Intraperitoneal Chemotherapy 3Gemcitabine 3FANG vaccine 3Biopsy 3osimertinib 2olaparib 2niraparib 2durvalumab 2adavosertib 2Trastuzumab 2Topotecan 2Taxes 2Standard of Care 2Sentinel Lymph Node Biopsy 2Saline Solution 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Oxaliplatin 2Nivolumab 2Music Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Neoplasms × gedatolisib × Gynecologic × Clear all
NCT01420081 2019-01-08

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Pfizer

Phase 2 Terminated
67 enrolled 37 charts
Gynecologic

Neoplasm Metastasis, Neoplasms, Recurrence, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡